Keros Therapeutics, Inc.

Biotechnology • Healthcare • Lexington, MA, United States • KROS (NGM)

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.3% - Time to Sell? - MarketBeat

MarketBeat • Jan 2

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance

Yahoo Finance • Dec 22

Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha

Seeking Alpha • Sep 25

Keros Therapeutics Announces Final Results of Tender Offer - GlobeNewswire

GlobeNewswire • Nov 20

Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer - Stock Titan

Stock Titan • Nov 19

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Keros Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Keros Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Keros Therapeutics, Inc. have?

Keros Therapeutics, Inc. has approximately 82 employees.

What industry is Keros Therapeutics, Inc. in?

Keros Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Keros Therapeutics, Inc. a publicly traded company?

Yes, Keros Therapeutics, Inc. is publicly traded under the ticker symbol KROS on the NGM. The company has a market capitalization of approximately $0.64 billion.

Where is Keros Therapeutics, Inc. headquartered?

Keros Therapeutics, Inc. is headquartered in Lexington, MA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.